Browse by Phase
Phase 1 Clinical Trials
Phase 1 trials test a new drug or treatment in a small group (20–80 people) for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects.
Total Trials
589
Recruiting Now
589
Top Conditions in Phase 1
Frequently Asked Questions — Phase 1 Trials
What is tested in a Phase 1 clinical trial?
Phase 1 trials test a new drug or treatment in a small group of 20–80 people for the first time. The primary goals are to evaluate safety, determine a safe dosage range, identify side effects, and study how the drug is metabolized and excreted. Phase 1 trials typically enroll patients with the target condition who have exhausted standard treatment options, or healthy volunteers in some cases.
How long do Phase 1 clinical trials last?
Phase 1 trials typically last several months to one year depending on the drug, dose-escalation protocol, and follow-up period. The relatively small patient cohort and focused safety objectives make Phase 1 the shortest stage in clinical development. Some are extended into Phase 1/2 combined designs to simultaneously gather early efficacy signals.
Are Phase 1 clinical trials safe to join?
Phase 1 trials are the first human tests of a new intervention and carry the most uncertainty about safety. All Phase 1 studies must be approved by an Institutional Review Board (IRB) and operate under strict FDA oversight. Participants receive intensive monitoring throughout the study. While risks exist, Phase 1 protocols use conservative dosing and frequent safety assessments to protect participants.
Active Phase 1 Studies
NCT06119256 Phase 1
Recruiting
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Condition
EBV Infection After Allogenic HSCT
Enrollment
12 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT07224425 Phase 1
Recruiting
A Study of BI 3810944 in Patients With Advanced Cancer
Condition
Solid Tumours
Enrollment
69 pts
Location
United States, Belgium, Netherlands
Sponsor
Boehringer Ingelheim
NCT05107674 Phase 1
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
Condition
Ovarian Cancer, Epithelial
Enrollment
345 pts
Location
United States, United Kingdom
Sponsor
Nurix Therapeutics, Inc.
NCT06966388 Phase 1
Recruiting
Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in ...
Condition
Breast Cancer
Enrollment
33 pts
Location
United States
Sponsor
Virginia Commonwealth Universi
NCT07586618 Phase 1
Recruiting
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Har...
Condition
Lymphoblastic Lymphoma
Enrollment
24 pts
Location
United States
Sponsor
Allterum Therapeutics, Inc
NCT06592703 Phase 1
Recruiting
Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of ...
Condition
Multiple Sclerosis
Enrollment
10 pts
Location
France
Sponsor
Rennes University Hospital
NCT07741461 Phase 1
Recruiting
ACT201 Injection in Healthy Participants and Participants With Chronic Hepatitis...
Condition
Chronic Hepaititis B
Enrollment
72 pts
Location
China
Sponsor
Xiamen Amoytop Biotech Co., Lt
NCT06717880 Phase 1
Recruiting
A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With...
Condition
Advanced Malignancies
Enrollment
260 pts
Location
China
Sponsor
Union Hospital, Tongji Medical
NCT06257680 Phase 1
Recruiting
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
15 pts
Location
China
Sponsor
Beijing Xunsheng Biomedical Re
NCT07361562 Phase 1
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Soli...
Condition
Advanced Solid Tumor, Adult
Enrollment
100 pts
Location
United States
Sponsor
Cogent Biosciences, Inc.
NCT07413042 Phase 1
Recruiting
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOT...
Condition
SCLC, Extensive Stage
Enrollment
24 pts
Location
China
Sponsor
Peking University Cancer Hospi
NCT07128680 Phase 1
Recruiting
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic ...
Condition
Advanced Clear Cell Renal Cell Carcinoma
Enrollment
33 pts
Location
United States
Sponsor
City of Hope Medical Center
NCT06857227 Phase 1
Recruiting
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid...
Condition
Rheumatoid Arthritis
Enrollment
54 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C
NCT05748197 Phase 1
Recruiting
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Condition
Acute Myeloid Leukemia
Enrollment
40 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT01245179 Phase 1
Recruiting
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Condition
Sickle Cell Disease
Enrollment
18 pts
Location
United States
Sponsor
Abdullah Kutlar
NCT06867497 Phase 1
Recruiting
A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safe...
Condition
Metastatic Adenocarcinoma of the Pancreas
Enrollment
20 pts
Location
South Korea
Sponsor
Boryung Pharmaceutical Co., Lt
NCT07456046 Phase 1
Recruiting
A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tu...
Condition
KRAS P.G12D
Enrollment
42 pts
Location
United States, Australia, South Korea
Sponsor
D3 Bio (Wuxi) Co., Ltd
NCT06345027 Phase 1
Recruiting
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Condition
Leukemia, Myeloid, Acute
Enrollment
78 pts
Location
United States
Sponsor
Baylor College of Medicine
NCT07204977 Phase 1
Recruiting
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Scler...
Condition
Amyotrophic Lateral Sclerosis
Enrollment
30 pts
Location
United States
Sponsor
National Institute of Neurolog
NCT07559019 Phase 1
Recruiting
Safety and Preliminary Activity of BI115 in Advanced SCLC
Condition
Small Cell Lung Cancer (SCLC)
Enrollment
150 pts
Location
China
Sponsor
Innovent Biologics (Suzhou) Co
NCT06816992 Phase 1
Recruiting
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon...
Condition
Solid Tumors
Enrollment
76 pts
Location
United States, Australia, Canada
Sponsor
ORIC Pharmaceuticals
NCT05445011 Phase 1
Recruiting
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refra...
Condition
Acute Myeloid Leukemia
Enrollment
12 pts
Location
China
Sponsor
Union Hospital, Tongji Medical
NCT06392711 Phase 1
Recruiting
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xero...
Condition
Xerostomia
Enrollment
36 pts
Location
United States
Sponsor
University of Wisconsin, Madis
NCT06492122 Phase 1
Recruiting
Study With [225Ac]Ac-FL-020 in mCRPC Participants
Condition
Metastatic Castration-resistant Prostate Cancer
Enrollment
50 pts
Location
United States, Australia, China
Sponsor
Full-Life Technologies UK Limi
NCT06022029 Phase 1
Recruiting
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in ...
Condition
Triple Negative Breast Cancer
Enrollment
168 pts
Location
United States, Australia
Sponsor
OncoNano Medicine, Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology